PET/CT for Therapy Response Assessment in Lymphoma

PET with 18F-FDG is a standard staging procedure for most lymphoma subtypes. Performed during and after therapy for Hodgkin lymphoma (HL) and aggressive non-Hodgkin lymphoma (NHL), 18F-FDG PET results have a high prognostic value and correlate with survival. 18F-FDG PET has been incorporated into revised response criteria for aggressive lymphomas, and several ongoing trials are under way to investigate the value of treatment adaptation based on early 18F-FDG PET results for HL and aggressive NHL. There is little evidence to support the use of 18F-FDG PET for monitoring of the treatment of indolent lymphomas and for routine use in the surveillance setting. So that trial results can be compared and translated easily into clinical practice, uniform and evidence-based guidelines for the interpretation and reporting of response monitoring scans are warranted. Because it is still not proven that the use of interim 18F-FDG PET can improve patient outcomes, we recommend examination of the use of 18F-FDG PET for response monitoring in appropriately designed clinical trials.

[1]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Baccarani,et al.  Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. , 2007, Clinical lymphoma & myeloma.

[3]  P. Dupont,et al.  Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. , 2003, Blood.

[4]  L. Mortelmans,et al.  Hodgkin lymphoma: Response assessment by Revised International Workshop Criteria , 2007, Leukemia & lymphoma.

[5]  P. Solal-Céligny,et al.  Follicular lymphoma international prognostic index , 2006, Blood.

[6]  P. Dupont,et al.  Can positron emission tomography with [18F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? , 2001, British journal of haematology.

[7]  J Kotzerke,et al.  Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. , 1999, Acta oncologica.

[8]  U. Jaeger,et al.  Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation , 2002, Leukemia.

[9]  C D Claussen,et al.  Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. , 2001, Oncology reports.

[10]  G. Jerusalem,et al.  Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. , 1999, Nuclear medicine communications.

[11]  L. Mortelmans,et al.  Aggressive and indolent non-Hodgkin's lymphoma: Response assessment by Integrated International Workshop Criteria , 2007, Leukemia & lymphoma.

[12]  F. d'Amore,et al.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Luca Nassi,et al.  18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results. , 2005, Oncology reports.

[14]  M. Phelps,et al.  Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. , 2003, Chest.

[15]  L. Specht,et al.  PET/CT in the management of haematological malignancies , 2008, European journal of haematology.

[16]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[17]  M. O'Doherty,et al.  FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Klemens Scheidhauer,et al.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  V. Diehl,et al.  Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. , 2001, Blood.

[20]  P. Gaulard,et al.  Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  O. Hoekstra,et al.  Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  J. Leonard,et al.  PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  R. Buchert,et al.  18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  H. Amthauer,et al.  Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. , 2008, Blood.

[25]  F. Maul,et al.  Whole body positron emission tomography in the treatment of Hodgkin disease , 2001, Cancer.

[26]  Martin Hutchings,et al.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.

[27]  A. Luciani,et al.  Quantitative CT analysis for assessing response in lymphoma (Cheson’s criteria) , 2005, Cancer imaging : the official publication of the International Cancer Imaging Society.

[28]  P. Dupont,et al.  Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  M. Sautter‐Bihl,et al.  Clinical Relevance of Positron Emission Tomography (PET) in Treatment Control and Relapse of Hodgkin's Disease , 2001, Strahlentherapie und Onkologie.

[30]  U. Cremerius,et al.  Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. , 1998, Nuclear medicine communications.

[31]  D. Weisenburger,et al.  Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Alavi,et al.  Utility of FDG-PET scanning in lymphoma by WHO classification. , 2003, Blood.

[33]  G. Jerusalem,et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. , 1999, Blood.

[34]  L. Avioli,et al.  Hodgkin's disease , 1969, Bone Marrow Transplantation.

[35]  S. Faria,et al.  FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. , 2005, Radiographics : a review publication of the Radiological Society of North America, Inc.

[36]  S. Hain,et al.  18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  G. Jerusalem,et al.  Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. , 2000, Haematologica.

[38]  J. Yahalom.  Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: A randomized study caveat , 2007, Leukemia & lymphoma.

[39]  R. Hustinx,et al.  Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  D. Bumann,et al.  Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  N. Mikhaeel,et al.  Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  S. Pileri,et al.  Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  P. Dupont,et al.  Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  E. Yoshikawa,et al.  Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[45]  Steve Y. Cho,et al.  Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[46]  S. Reske.  PET and restaging of malignant lymphoma including residual masses and relapse , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[47]  A. Padhani,et al.  Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? , 2000, European journal of cancer.

[48]  S. Rankin.  Assessment of response to therapy using conventional imaging , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[49]  R. Fisher,et al.  Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  R Paul,et al.  Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[51]  A. Buck,et al.  Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography , 1998, European Journal of Nuclear Medicine.

[52]  Emmanuel Itti,et al.  [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. , 2005, Blood.

[53]  J. Leonard,et al.  FDG‐PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease , 2006, Cancer.

[54]  T. Lister,et al.  Interim results of a UK NCRI randomised trial comparing involved field radiotherapy with no further treatment after 3 cycles ABVD and a negative PET scan in clinical stages IA/IIA Hodgkin lymphoma , 2007 .

[55]  J. Vose,et al.  Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Y. Erdi,et al.  Schöder H, Noy A, Gönen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 23: 4643-4651 , 2005 .

[57]  B Beuthien-Baumann,et al.  Prognostic value of positron emission tomography in the evaluation of post‐treatment residual mass in patients with Hodgkin's disease and non‐Hodgkin's lymphoma , 2001, British journal of haematology.

[58]  J. Armitage,et al.  A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.

[59]  Ronald R Price,et al.  FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. , 2003, International journal of radiation oncology, biology, physics.

[60]  S. Hain,et al.  18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CT , 2000, Leukemia & lymphoma.

[61]  S. Pileri,et al.  Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. , 2007, Haematologica.

[62]  M. Blaufox,et al.  A metaanalysis of 18F‐2‐deoxy‐2‐fluoro‐D‐glucose positron emission tomography in the staging and restaging of patients with lymphoma , 2005, Cancer.

[63]  F. Bénard,et al.  Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[64]  G. Canellos,et al.  Residual mass in lymphoma may not be residual disease. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  J. Wildberger,et al.  Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma , 2002, Bone Marrow Transplantation.

[66]  A. Levis,et al.  The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. , 2006, Haematologica.

[67]  J. Richter,et al.  Positron Emission Tomography Using 18F-Fluorodeoxyglucose for the Evaluation of Residual Hodgkin's Disease Mediastinal Masses , 2004, Leukemia & lymphoma.

[68]  Lotty Hooft,et al.  18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. , 2006, Haematologica.

[69]  A G Stansfeld,et al.  Patterns of survival in patients with Hodgkin's disease: long follow up in a single centre. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[70]  V. Diehl,et al.  Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. , 2003, The New England journal of medicine.

[71]  Thomas Beyer,et al.  FDG-PET/CT in re-staging of patients with lymphoma , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[72]  M Tubiana,et al.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  E. Moser,et al.  Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET? , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[74]  J. Armitage,et al.  Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma , 2007, Leukemia & lymphoma.

[75]  M. Salvatore,et al.  Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans , 2007, Leukemia & lymphoma.

[76]  A. Nagler,et al.  Combined escBEACOPP-ABVD Therapy for Advanced Hodgkin’s Lymphoma Patients with High IPS Score: An Effective Regimen and Low Positive Predictive Value of Early FDG-PET/CT Scan. , 2007 .

[77]  L. Brepoels,et al.  PET and PET/CT for response evaluation in lymphoma: Current practice and developments , 2007, Leukemia & lymphoma.

[78]  Y. Erdi,et al.  Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  A. Becherer,et al.  Prognostic value of FDG-PET in malignant lymphoma. , 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.